The Management of Co-Morbidities in Patients with Heart Failure - Iron Deficiency

Stephan von Haehling, Ewa Jankowska, Stefan D Anker


Co-morbidities have been recognised as playing a crucial role in the progress of the older patient with HF in particular. The 2016 ESC/HFA HF guidelines stress the significance of co-morbidities more than any previous guidelines have. Iron deficiency is a co-morbidity, that has received very little attention until the last decade, as evidence has accumulated both for the significance of this co-morbidity and the emergence of safe effective therapies that appear to offer significant benefits to the HF population who suffer this co-morbidity.


Heart Failure; Cardiology; Guidelines; Iron Deficiency; Anaemia

Full Text:



Ponikowski P, Voors A, Anker S et al The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure. Published online 26 May 2016

O’Meara, E; Rouleau JL; White, M; et al. Heart Failure With Anemia. Circ Heart Fail. 2014;7:773-781

Swedberg, K, Young JB, Anand, IS, et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure N Engl J Med 2013; 368:1210-1219

Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJ, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34:827-34

I.T. Klip, J. Comin-Colet, A.A. Voors, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J, 165 (2013), pp. 575–582.e3

O'Meara E; de Denus S; Lepage S. Heart Failure, Iron Deficiency, and Supplementation: Where Do We Stand?. Canadian Journal of Cardiology. 32(2):148-50, 2016 Feb.

E.A. Jankowska, S. von Haehling, S.D. Anker, I.C. Macdougall, P. Ponikowski. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives Eur Heart J, 34 (2013), pp. 816–829

M.T. Maeder, O. Khammy, C. dos Remedios, D.M. Kaye. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol, 58 (2011), pp. 474–480

Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in pa- tients with heart failure and iron deficiency. N Engl J Med 2009;361:2436 – 2448.

P. Ponikowski, D.J. van Veldhuisen, J. Comin-Colet, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J, 36 (2015), pp. 657–668

C. Qian, B. Wei, J. Ding, H. Wu, Y. Wang. The efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a systematic review and meta-analysis. Can J Cardiol, 32 (2016), pp. 151–159

G. Arutyunov, N. Bylova, A. Ivleva, Z. Kobalava. The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose in patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur J Heart Fail Suppl, 8 (2009) Abstract 141

D.O. Okonko, A. Grzeslo, T. Witkowski, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol, 51 (2008), pp. 103–112

J.E. Toblli, A. Lombrana, P. Duarte, F. Di Gennaro. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol, 50 (2007), pp. 1657–1665

Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Eur J Heart Fail. 2016 Jan 28. doi: 10.1002/ejhf.473.

Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal. 2015;2:2.


Copyright (c) 2017 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.